They further confirmed that co-expression of Lyn and Syk was required to fully induce resistance to nilotinib in drug-sensitive CML cells and that inhibition of Syk restored the capacity of nilotinib to inhibit cell proliferation38. The gene discussed is LYN; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.